Aehr Test Systems delivered the kind of quarter that is difficult to argue with on the numbers. Non-GAAP earnings of $0.28 per share beat the $0.11 consensus by 86.7% and cleared the $0.15 Earnings Whisper number by a wide margin. Record revenue of $33.01 million topped the $27.45 million consensus by 20.2% and grew 200.9% year over year. Earnings grew 1500.0% from a year-ago $0.01, and GAAP results swung from a $0.07 loss to a $0.21 profit. Management also raised its fiscal 2027 revenue outlook to $150 million, the top of the prior $130 million to $150 million range. The central tension is not in the report. It is that a business now accelerating on nearly every operating metric enters the quarter with shares down 44.1% since the last report and trading just above their inter-earnings low.

The quality of the beat holds up better than the surprise alone suggests. Revenue rose 75% sequentially, continuing a progression from $9.9 million two quarters earlier to $10.3 million, then $18.8 million, and now $33.0 million. Non-GAAP gross margin expanded to 48.5% from 45% last quarter and 36.5% the quarter before. Non-GAAP operating expenses barely moved, at $7.8 million versus $7.5 million, so non-GAAP operating income jumped to $8.2 million from under $1 million. GAAP net income of $7.2 million benefited from only a modest $0.25 million tax benefit, so the profit is operational rather than a tax artifact. One caveat on comparability: Aehr changed its fiscal year-end, so the quarter ended September 25, 2026, and is compared against the three months ended August 29, 2025.

The forward indicators were arguably stronger than the income statement. Bookings of $46.7 million produced a 1.4 book-to-bill ratio. Quarter-end backlog rose to $100.9 million from $80.6 million, and effective backlog reached $109.3 million. Consumables contributed $13.5 million, or 41% of revenue, and management expects about 35% for the year, above its roughly 30% long-term model. That mix points to a growing installed base generating recurring pull-through. Management now expects revenue to rise each quarter through fiscal Q4, replacing its earlier front-half-weighted view. It called the $150 million outlook conservative and said it is not supply-constrained. Reaching that figure implies about $117 million across the remaining three quarters, which looks well covered by backlog. The profitability target was also reframed as non-GAAP net income of at least 20% of revenue, up from an 18% to 22% pre-tax range.

The catalyst slate broadened meaningfully. A major supplier of AI accelerators, CPUs, and network processors moved from a completed benchmark to purchasing a full FOX-XP test cell for production evaluation at a Taiwan OSAT. Installation is planned for early calendar 2027, with a high-volume decision expected within months afterward. Management called it the largest burn-in opportunity Aehr has ever pursued and sized it at roughly $35 million to $70 million per million units. On the Sonoma side, the lead hyperscaler's second AI processor has qualified, follow-on orders are in hand, and the customer forecasts higher volumes than its first chip. Aehr is shipping more than a dozen Sonoma systems per month. Silicon photonics, silicon carbide, and GaN orders are also improving, and management now sees production potential across more than a dozen customers, versus a handful historically.

Bears still have legitimate ammunition. Operating cash use was $3.1 million in the quarter, as receivables rose $10.7 million and inventory rose $9.0 million. Combined with the transition month and $4.5 million of tax-withholding share repurchases, cash fell to $105.1 million from $116.5 million. Management guided fiscal Q2 gross margin below Q1's 48.5% because of heavier Sonoma mix. Other risks flagged on the call:

• The benchmark customer's Taiwan installation slipped about 30 days, and its production decision remains unconfirmed.
• Flash memory opportunities are progressing more slowly than expected.
• Competitive system-level-test "AI burn-in" offerings are entering the conversation.
• Customer concentration and quarterly lumpiness remain acknowledged risks.

The market setup is more complicated than the surprise implies. Shares peaked at a 52-week high of $147.40 on August 14 and then fell 62.8% to $54.89. That leaves them 26.0% below the 200-day moving average of $74.16 and only 6.1% above the October 30 low of $51.72. Investor sentiment became modestly more positive, rising to 0.2162 from 0.1254, but remains only mildly bullish. The Earnings Whispers trend readings are mixed, with momentum positive while price and AVWAP trends remain negative. That split reflects improving fundamentals against a stock that has been aggressively de-rated.

The bottom line is that Aehr produced a clean, broad-based acceleration: record revenue, rising margins, a 1.4 book-to-bill, more than $109 million in effective backlog, and a raised outlook that management itself calls conservative. The near-term blemishes are real but largely the cost of growth, namely inventory-driven cash use and Sonoma-related margin dilution. The larger swing factor is the pending production decision at the benchmark AI customer. With the stock entering the report near its lows rather than its highs, the fundamental story has moved further ahead of the share price than at any point in recent quarters.